Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Assets (2021 - 2025)

Fennec Pharmaceuticals filings provide 5 years of Other Non-Current Assets readings, the most recent being $717000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 12.77% to $717000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $717000.0, a 12.77% decrease, with the full-year FY2025 number at $717000.0, down 12.77% from a year prior.
  • Other Non-Current Assets hit $717000.0 in Q4 2025 for Fennec Pharmaceuticals, down from $743000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.0 million in Q1 2024 to a low of $14000.0 in Q2 2022.
  • Median Other Non-Current Assets over the past 5 years was $730000.0 (2025), compared with a mean of $526812.5.
  • Biggest five-year swings in Other Non-Current Assets: surged 833.02% in 2024 and later decreased 22.35% in 2025.
  • Fennec Pharmaceuticals' Other Non-Current Assets stood at $27000.0 in 2021, then skyrocketed by 681.48% to $211000.0 in 2022, then skyrocketed by 286.73% to $816000.0 in 2023, then grew by 0.74% to $822000.0 in 2024, then fell by 12.77% to $717000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $717000.0 (Q4 2025), $743000.0 (Q3 2025), and $768000.0 (Q2 2025) per Business Quant data.